Diffuse Midline Glioma, H3 K27M-Mutant — Trials

Diffuse Midline Glioma, H3 K27M-Mutant — Trials · CancerIndex

Clinical trials

Registered studies

28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 29%
Top sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07389278	Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)	not yet recruiting	Phase 1 / Phase 2	97	Sabine Mueller, MD, PhDOTHER	1	Sep 15, 2026	clinicaltrials

Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials